慢加急性肝衰竭合并感染的研究进展

卞佳乐; 韩涛

doi:10.12449/JCH260802

慢加急性肝衰竭合并感染的研究进展

DOI: 10.12449/JCH260802

卞佳乐,
韩涛^, ,

南开大学第一附属医院/天津市人民医院消化（肝病）科，天津 300121

基金项目:

国家自然科学基金 (82470660);

国家自然科学基金 (82170630)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：卞佳乐负责文献收集，起草撰写论文；韩涛负责设计论文框架，拟定写作思路，指导文章撰写、修改并定稿。

详细信息

通信作者:
韩涛， hantaomd@126.com （ORCID： 0000-0003-4216-6968）

计量
- 文章访问数: 15
- HTML全文浏览量: 1
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2026-05-06
- 录用日期: 2026-07-24
- 出版日期: 2026-08-25

Research advances in acute-on-chronic liver failure with infection

Jiale Bian,
Tao Han^{,
,}

Department of Gastroenterology and Hepatology，The First Affiliated Hospital of Nankai University/Tianjin People’s Hospital，Tianjin 300121，China

Research funding:

National Natural Science Foundation of China (82470660);

National Natural Science Foundation of China (82170630)

More Information

Corresponding author: Han Tao， hantaomd@126.com （ORCID： 0000-0003-4216-6968）

摘要

摘要: 感染既是慢加急性肝衰竭的常见诱因，也是其重要的并发症，与患者多器官功能衰竭及高病死率密切相关。本文围绕慢加急性肝衰竭合并感染的流行病学、临床与病原学特征、发病机制以及诊断和治疗策略的新进展进行系统综述，旨在为进一步优化此类患者的临床决策、探索新型诊治方法提供参考。
- 慢加急性肝功能衰竭 /
- 感染 /
- 诊断 /
- 治疗学
Abstract: Infection is not only a common predisposing factor for acute-on-chronic liver failure （ACLF）， but also a critical complication of ACLF， and it is closely associated with multiple organ failure and high mortality. This article systematically reviews the recent advances in the epidemiology， clinical and etiological features， pathogenesis， and diagnosis and treatment strategies of ACLF with infection， in order to provide guidance for further optimizing clinical decision-making and exploring novel diagnostic and treatment methods for such patients.
- Acute-On-Chronic Liver Failure /
- Infections /
- Diagnosis /
- Therapeutics

HTML全文

表 1 慢加急性肝衰竭合并感染的诊断指标与方法

Table 1. Diagnostic indicators and methods for acute-on-chronic liver failure complicated by infection

类型	指标或技术	临床应用情况
经典指标
细菌感染	C反应蛋白、降钙素原、白细胞计数及中性粒细胞比例等	常规应用
细菌感染	血液、腹水、尿液、痰液等病原学培养及药敏试验	常规应用
真菌感染	G试验、GM试验、隐球菌荚膜多糖抗原、涂片镜检、染色和组织病理检查、分子生物学诊断技术等	常规应用
新型标志物	可溶性CD14亚型^［38］、sTREM-1^［38］、sPD-L1^［35］、IL-1RA^［36］、PGE₂^［20］、IL-6^［39］、BTLA^［23］等	探索阶段
多指标联合模型	IL-1RA联合模型^［36］、GIC模型^［39］、WBD模型^［40］、整合蛋白质组学与临床变量联合模型^［34］等	探索阶段
其他新型技术	mNGS^［37］等	选择性应用
	MALDI-TOF MS	选择性应用
	多组学整合技术	探索阶段
注：G试验，1，3-β-D-葡聚糖试验；GM试验，曲霉半乳甘露聚糖试验；sTREM-1，可溶性髓系细胞触发受体1；sPD-L1，可溶性程序性死亡受体配体1；PGE₂，前列腺素E₂；IL-6，白细胞介素6；BTLA，B细胞和T细胞衰减因子；IL-1RA，白细胞介素1受体拮抗剂；GIC模型，球蛋白-白细胞介素6-C反应蛋白模型；WBD模型，白细胞计数-血尿素氮-D-二聚体模型；mNGS，宏基因组二代测序；MALDI-TOF MS，基质辅助激光解析电离-飞行时间质谱。

下载: 导出CSV

参考文献(54)

[1]	Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of acute-on-chronic liver failure(2025 version)[J]. J Prac Hepatol, 2025, 28( 5): 641- 647. DOI: 10.3969/j.issn.1672-5069.2025.05.001. 中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025年版)[J]. 实用肝脏病杂志, 2025, 28( 5): 641- 647. DOI: 10.3969/j.issn.1672-5069.2025.05.001.
[2]	Piano S, Bunchorntavakul C, Marciano S, et al. Infections in cirrhosis[J]. Lancet Gastroenterol Hepatol, 2024, 9( 8): 745- 757. DOI: 10.1016/S2468-1253(24)00078-5.
[3]	Wong F, Piano S, Singh V, et al. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure[J]. J Hepatol, 2021, 74( 2): 330- 339. DOI: 10.1016/j.jhep.2020.07.046.
[4]	Trebicka J, Fernandez J, Papp M, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis[J]. J Hepatol, 2021, 74( 5): 1097- 1108. DOI: 10.1016/j.jhep.2020.11.019.
[5]	Wang N, Tao S, Chen L. Construction and validation of HBV-ACLF bacterial infection diagnosis model based on machine learning[J]. BMC Infect Dis, 2025, 25( 1): 847. DOI: 10.1186/s12879-025-11199-5.
[6]	Thiyagarajah K, Sonnenberg J, Görgülü E, et al. Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure[J]. JHEP Rep, 2026, 8( 4): 101627. DOI: 10.1016/j.jhepr.2025.101627.
[7]	Hong C Z, Huang Z X, He Y L, et al. Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation[J]. Clin Mol Hepatol, 2025, 31( 4): 1316- 1332. DOI: 10.3350/cmh.2025.0332.
[8]	Liu Y S, Wang Q N, Huang P, et al. Phase characteristics and risk factors of acute-on-chronic liver failure with invasive pulmonary aspergillosis[J]. BMC Infect Dis, 2025, 25( 1): 1189. DOI: 10.1186/s12879-025-11518-w.
[9]	Xu Z, Zhang X, Chen J, et al. Bacterial infections in acute-on-chronic liver failure: Epidemiology, diagnosis, pathogenesis, and management[J]. J Clin Transl Hepatol, 2024, 12( 7): 667- 676. DOI: 10.14218/JCTH.2024.00137.
[10]	Barros N, Rosenblatt R E, Phipps M M, et al. Invasive fungal infections in liver diseases[J]. Hepatol Commun, 2023, 7( 9): e0216. DOI: 10.1097/HC9.0000000000000216.
[11]	Severe Liver Disease Group, the Professional Committee for Hepatology, Chinese Research Hospital Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease[J]. J Clin Hepatol, 2022, 38( 2): 311- 317. DOI: 10.3969/j.issn.1001-5256.2022.02.011. 中国研究型医院学会肝病专业委员会重症肝病学组, 中华医学会肝病学分会重型肝病与人工肝学组. 重症肝病合并侵袭性真菌感染诊治专家共识[J]. 临床肝胆病杂志, 2022, 38( 2): 311- 317. DOI: 10.3969/j.issn.1001-5256.2022.02.011.
[12]	Yao R Y, Xu G F, Fu X J, et al. Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: A multicenter paired cohort study[J]. Front Cell Infect Microbiol, 2024, 14: 1471974. DOI: 10.3389/fcimb.2024.1471974.
[13]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023, 79( 2): 461- 491. DOI: 10.1016/j.jhep.2023.04.021.
[14]	Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis[J]. Clin Mol Hepatol, 2021, 27( 3): 437- 445. DOI: 10.3350/cmh.2020.0329.
[15]	Hernández-Tejero M, Pavesi M, Aziz F, et al. Multidrug-resistant colonization in decompensated cirrhosis outside the ICU predicts infection and poor outcomes[J]. JHEP Rep, 2026, 8( 3): 101707. DOI: 10.1016/j.jhepr.2025.101707.
[16]	Choudhury A, Kulkarni A V, Arora V, et al. Acute-on-chronic liver failure(ACLF): The‘Kyoto consensus’-steps from Asia[J]. Hepatol Int, 2025, 19( 1): 1- 69. DOI: 10.1007/s12072-024-10773-4.
[17]	Zhang Q, Hu J X, Qiu S T, et al. Clinical differences between HBV and alcohol related ACLF in a WGO classification multicenter study[J]. Sci Rep, 2025, 15( 1): 25292. DOI: 10.1038/s41598-025-09620-9.
[18]	McGettigan B, Hernandez-Tejero M, Malhi H, et al. Immune dysfunction and infection risk in advanced liver disease[J]. Gastroenterology, 2025, 168( 6): 1085- 1100. DOI: 10.1053/j.gastro.2024.08.046.
[19]	Liang X, Luo J J, Zhou Q, et al. Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression[J]. Gut, 2026, 75( 2): 367- 381. DOI: 10.1136/gutjnl-2024-333308.
[20]	Maini A A, Becares N, China L, et al. Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway[J]. JHEP Rep, 2021, 3( 6): 100332. DOI: 10.1016/j.jhepr.2021.100332.
[21]	Geng A, Brenig R G, Roux J, et al. Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges[J]. J Hepatol, 2025, 83( 1): 146- 160. DOI: 10.1016/j.jhep.2024.12.031.
[22]	Yu X, Tian W H, Bao X W, et al. Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure[J]. Hepatology, 2026, 83( 5): 1174- 1191. DOI: 10.1097/hep.0000000000001427.
[23]	Yu X P, Yang F F, Shen Z L, et al. BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4⁺ T-cell exhaustion[J]. Nat Commun, 2024, 15( 1): 1835. DOI: 10.1038/s41467-024-46047-8.
[24]	Clària J, Arroyo V, Moreau R. Roles of systemic inflammatory and metabolic responses in the pathophysiology of acute-on-chronic liver failure[J]. JHEP Rep, 2023, 5( 9): 100807. DOI: 10.1016/j.jhepr.2023.100807.
[25]	Simbrunner B, Caparrós E, Neuwirth T, et al. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response[J]. Hepatol Int, 2023, 17( 4): 1045- 1056. DOI: 10.1007/s12072-023-10496-y.
[26]	Cao Z J, Yao Y J, Cai M H, et al. Blood markers for type-1,-2, and-3 inflammation are associated with severity of acutely decompensated cirrhosis[J]. J Hepatol, 2025, 82( 5): 836- 850. DOI: 10.1016/j.jhep.2024.10.028.
[27]	Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol, 2021, 75( Suppl 1): S67- S81. DOI: 10.1016/j.jhep.2020.11.013.
[28]	Lee S, Arefaine B, Begum N, et al. Oral-gut microbiome interactions in advanced cirrhosis: Characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance[J]. J Hepatol, 2025, 82( 4): 622- 633. DOI: 10.1016/j.jhep.2024.09.046.
[29]	Jin S, Cenier A, Wetzel D, et al. Microbial collagenase activity is linked to oral-gut translocation in advanced chronic liver disease[J]. Nat Microbiol, 2026, 11( 1): 211- 227. DOI: 10.1038/s41564-025-02223-0.
[30]	Bajaj J S, Silvey S, Aljabi A, et al. Dental prophylactic interventions are associated with lower decompensation-related hospitalizations over 2 years in cirrhosis[J]. JHEP Rep, 2026, 8( 5): 101821. DOI: 10.1016/j.jhepr.2026.101821.
[31]	Bao Z W, Wei R N, Zheng X P, et al. Landscapes of gut microbiome and bile acid signatures and their interaction in HBV-associated acute-on-chronic liver failure[J]. Front Microbiol, 2023, 14: 1185993. DOI: 10.3389/fmicb.2023.1185993.
[32]	Bajaj J S, Reddy K R, O’Leary J G, et al. Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis[J]. Gastroenterology, 2020, 159( 5): 1715- 1730. DOI: 10.1053/j.gastro.2020.07.019.
[33]	Chen T, Chen G, Wang G Q, et al. Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections[J]. Hepatol Int, 2024, 18( 3): 817- 832. DOI: 10.1007/s12072-023-10637-3.
[34]	Xiong F X, Zheng J M, Chen J J, et al. Proteomics-based machine learning model for predicting secondary infection in HBV-related liver failure[J]. Nat Commun, 2026, 17: 3667. DOI: 10.1038/s41467-026-69075-y.
[35]	Juanola A, Mezzano G, Pose E, et al. PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study[J]. JHEP Rep, 2025, 7( 12): 101597. DOI: 10.1016/j.jhepr.2025.101597.
[36]	Konstantis G, Schütte A, Jung B, et al. IL-1 receptor antagonist as a diagnostic biomarker for bacterial infections in acute decompensation of cirrhosis[J]. Sci Rep, 2025, 15: 43266. DOI: 10.1038/s41598-025-30647-5.
[37]	Liu Y S, Zhang Q, Li J, et al. mNGS improves the efficiency of infection diagnosis and treatment in acute-on-chronic liver failure[J]. BMC Gastroenterol, 2026, 26( 1): 129. DOI: 10.1186/s12876-025-04601-8.
[38]	Chen J, Huang Z B, Li H, et al. Early diagnostic biomarkers of sepsis for patients with acute-on-chronic liver failure: A multicenter study[J]. Infect Dis Ther, 2021, 10( 1): 281- 290. DOI: 10.1007/s40121-020-00362-x.
[39]	Zhang Z W, Ma K, Yang Z Y, et al. Development and validation of a clinical predictive model for bacterial infection in hepatitis B virus-related acute-on-chronic liver failure[J]. Infect Dis Ther, 2021, 10( 3): 1347- 1361. DOI: 10.1007/s40121-021-00454-2.
[40]	Sun R, Lu W L, Ren W H, et al. A novel laboratory-based nomogram for assessing infection presence risk in acute-on-chronic liver failure patients[J]. Sci Rep, 2023, 13( 1): 16970. DOI: 10.1038/s41598-023-44006-9.
[41]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2024 version)[J]. J Clin Hepatol, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.
[42]	Lin Y X, Yu X P, Lin H M, et al. Effect of nucleos(t)ide analogues withdrawal on survival outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Aliment Pharmacol Ther, 2025, 62( 5): 504- 511. DOI: 10.1111/apt.70213.
[43]	Maiwall R, Piano S, Singh V, et al. Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections-Results from the ICA“Global Study”(EABCIR-Global Study)[J]. Hepatology, 2024, 79( 5): 1019- 1032. DOI: 10.1097/HEP.0000000000000653.
[44]	Tang F J, Yuan H X, Li X H, et al. Effect of delayed antibiotic use on mortality outcomes in patients with sepsis or septic shock: A systematic review and meta-analysis[J]. Int Immunopharmacol, 2024, 129: 111616. DOI: 10.1016/j.intimp.2024.111616.
[45]	Kulkarni A V, Avadhanam M, Karandikar P, et al. Antibiotics with or without rifaximin for acute hepatic encephalopathy in critically ill patients with cirrhosis: A double-blind, randomized controlled(ARiE) trial[J]. Am J Gastroenterol, 2024, 119( 5): 864- 874. DOI: 10.14309/ajg.0000000000002575.
[46]	Verma N, Valsan A, Garg P, et al. Empirical antifungal therapy improves survival in patients with acute-on-chronic liver failure with suspected invasive fungal infections: A pragmatic randomized trial[J]. Am J Gastroenterol, 2025. DOI: 10.14309/ajg.0000000000003832.[ Epub ahead of print]
[47]	Prescott H C, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2026[J]. Crit Care Med, 2026, 54( 4): 725- 812. DOI: 10.1097/CCM.0000000000007075.
[48]	Li J X, Xie S H, Chen M L, et al. Panose prevents acute-on-chronic liver failure by reducing bacterial infection in mice[J]. J Clin Invest, 2025, 135( 14): e184653. DOI: 10.1172/JCI184653.
[49]	Trebicka J, Hernaez R, Shawcross D L, et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure(ACLF) and the role of biomarkers[J]. Gut, 2024, 73( 6): 1015- 1024. DOI: 10.1136/gutjnl-2023-330584.
[50]	Korf H, du Plessis J, van Pelt J, et al. Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity[J]. Gut, 2019, 68( 10): 1872- 1883. DOI: 10.1136/gutjnl-2018-316888.
[51]	Xiang X G, Feng D C, Hwang S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice[J]. J Hepatol, 2020, 72( 4): 736- 745. DOI: 10.1016/j.jhep.2019.11.013.
[52]	Xiang L, An Z, Wu X Y, et al. Carbon dot-loaded apoptotic vesicles improve the liver Kupffer cell-mediated antibacterial effect to synergistically alleviate sepsis[J]. ACS Nano, 2024, 18( 26): 16726- 16742. DOI: 10.1021/acsnano.4c01780.
[53]	Ma C H, Zhou Y Z, Yang Z C, et al. Kupffer cells biomimetic nanoparticles alleviate sepsis related liver injury[J]. J Nanobiotechnology, 2025, 23( 1): 756. DOI: 10.1186/s12951-025-03860-7.
[54]	Chaudhary D, Kausar R, Lee J, et al. Bioengineered hybrid spheroids integrating mesenchymal stem cells and metformin-loaded microspheres for the treatment of sepsis-induced liver injury[J]. J Control Release, 2026, 393: 114798. DOI: 10.1016/j.jconrel.2026.114798.